ClinicalTrials.gg
RecruitingNCT07735286Updated Oct 21, 2026

Automating Tobacco Cessation in Primary Care

An interventional study of Tobacco counseling resources in Tobacco Use and Tobacco Use Cessation, sponsored by University of Pennsylvania. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by University of Pennsylvania · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 21, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4,800
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 313 studies in Tobacco Use with a site in United States — 54 open to participants now, 65 under way, 1 of them phase 3. Tobacco Use · United States.

Planned enrollment
5th of 288
4,800 · median 120
Started
2026
with 13 others
No phase
233 of 313
40 open now
Primary completion
2027-03
later than 21 of 64 live
Registered
306th of 313
by date

Among the 313 studies in Tobacco Use with a site in United States, this one is the 5th largest by planned enrollment of the 288 interventional ones that give a count, is one of 14 that started in 2026, is one of 233 with no phase, reaches primary completion later than 21 of the 64 other live ones, and was the 306th registered.

Tobacco Use

423 studies on the registry are indexed under Tobacco Use; 85 are open to participants now.

Browse Tobacco Use studies →

Open to participants now

54 of the 313 studies in Tobacco Use with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 54 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Tobacco Use studies recruiting now, 28 (55%) set no upper age limit and 19 (37%) stop at 75 or younger; 2 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 313 studies in Tobacco Use with a site in United States, or all of them as a file.
02

Study summary

This study focuses on improving how primary care teams identify patients who smoke and offer access to nicotine replacement therapy, or NRT. NRT includes medications such as nicotine patches, gum, or lozenges that can reduce cravings and support people who are interested in cutting back or quitting smoking. Although NRT is an evidence-based treatment option, it is not always discussed or prescribed during routine primary care visits. To better understand how NRT can be offered in primary care, the project will test a workflow at Penn Family Care that identifies patients who currently smoke and provides information about available tobacco treatment options. Edward Cooper Internal Medicine will serve as a comparison site. Patients who smoke and/or are prescribed NRT will also receive a 30-day follow-up survey to learn whether they received, picked up, or used NRT; whether it was useful; and what barriers they experienced.

03

Conditions studied

  • Tobacco Use
  • Tobacco Use Cessation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Patient at Penn Family Care or Edward Cooper Internal Medicine
  • Had an eligible scheduled or completed practice visit categorized as a new annual visit, return patient visit, return annual visit, or return patient sick visit
  • For the tobacco cessation intervention: Penn Family Care patient who had not previously completed the tobacco questionnaire
  • For the 30-day follow-up survey: Active smoker in the EHR as of the completed visit date or prescribed nicotine replacement therapy (NRT) between 3 days before and 30 days after the completed visit date
  • For the primary analysis: Active smoker in the EHR as of the completed visit date
  • For the primary analysis: Did not have an NRT prescription between 34 and 4 days before the completed visit date

Exclusion criteria

Exclusion Criteria:

  • None except as specified in inclusion criteria.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
4,800 participants (estimated)

Study arms

  • Experimental
    Penn Family Care (Treatment)

    Interested participants will receive a text with tobacco counseling resources

    Behavioral: Tobacco counseling resources

  • No intervention
    Arm 2: Edward Cooper Internal Medicine (Usual Practice)

    No text with tobacco counseling resources

Interventions

  • BehavioralTobacco counseling resources

    Participants who are in the intervention arm will receive tobacco counseling resources via the Way to Health platform. Way to Health will send text message links to tobacco cessation counseling resources (PA Quitline and/or SmokeFreeTXT).

06

What researchers measure

Primary outcomes

  1. Proportion of Active Smokers with a Signed NRT Prescription

    The primary outcome will be proportion of patients with a signed NRT prescription (signed between 3 days prior to scheduled visit and 30 days after completed visit) among those documented as active smokers in the EHR as of this visit who did not have an NRT prescription in the 34 to 4 days prior. A sensitivity analysis will include additional patients identified as smokers through pre-visit surveys.

    Time frame: From 3 days before scheduled visit and 30 days after completed visit.

Secondary outcomes

  1. Sensitivity of EHR Active Smoker Designation

    Sensitivity of EHR active smoker designation using tobacco questionnaire response as benchmark (Treatment-site Secondary Outcome Measure 1)

    Time frame: At completion of pre-visit tobacco questionnaire (baseline)

  2. Specificity of EHR Active Smoker Designation

    Specificity of EHR active smoker designation using tobacco questionnaire response as benchmark (Treatment-site Secondary Outcome Measure 2)

    Time frame: At completion of pre-visit tobacco questionnaire (baseline)

  3. Accuracy of EHR Active Smoker Designation

    Accuracy of EHR active smoker designation using tobacco questionnaire response as benchmark (Treatment-site Secondary Outcome Measure 3)

    Time frame: At completion of pre-visit tobacco questionnaire (baseline)

  4. Proportion of Tobacco Questionnaire-Identified Smokers Selecting Each Benefit of Quitting

    Proportion of tobacco questionnaire-identified smokers who select each benefit of quitting (Treatment-site Secondary Outcome Measure 4)

    Time frame: At completion of the pre-visit tobacco questionnaire (baseline)

  5. Proportion of Tobacco Questionnaire-Identified Smokers Selecting Each of the Three Treatments

    Proportion who select each of the three treatments (Treatment-site Secondary Outcome Measure 5)

    Time frame: At completion of the pre-visit tobacco questionnaire (baseline)

  6. Proportion of Participants Selecting NRT Whose Clinician Signs the Pended Order

    Proportion selecting NRT whose clinician signs the pended order (Treatment-site Secondary Outcome Measure 6)

    Time frame: From completion of the pre-visit tobacco questionnaire through 30-days after the completed visit

  7. Proportion of Participants With Any NRT Prescription Recorded in the EHR

    Any NRT prescription in the EHR during the study period (Both-sites Secondary Outcome Measure 7)

    Time frame: From study start for first participant to 6 months later

  8. Proportion of Participants Reporting NRT Use at 30-Day Follow-Up

    30-day self-reported NRT use (Both-sites Secondary Outcome Measure 8)

    Time frame: 30 days after completed visit, at time of follow-up survey completion

  9. Proportion of Participants Reporting Engagement With Tobacco Cessation Counseling Resources at 30-Day Follow-Up

    30-day self-reported engagement with tobacco cessation counseling resources (Both-sites Secondary Outcome Measure 9)

    Time frame: 30 days after completed visit, at time of follow-up survey completion

  10. Proportion of Participants Reporting Each Smoking Status at 30-Day Follow-Up

    30-day self-reported smoking status (Both-sites Secondary Outcome Measure 10)

    Time frame: 30 days after completed visit, at time of follow-up survey completion

  11. Proportion of Participants Reporting Changes in Smoking Behavior at 30-Day Follow-Up

    30-day self-reported changes in smoking behavior (Both-sites Secondary Outcome Measure 11)

    Time frame: 30 days after completed visit, at time of follow-up survey completion

  12. Proportion of Participants With a New or Refill NRT Prescription Recorded in the EHR

    New/refill NRT prescription in EHR 30-60 days after completed visit (Both-sites Secondary Outcome Measure 12)

    Time frame: 30 to 60 days after the completed visit

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Mar 2027, 5 months after the start.

Of 167 non-industry interventional studies with no phase under Tobacco Use, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 5 months is below that.

Counting every sponsor, half of 224 studies reached it within 16 months; a quarter within 5 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2026
First posted
Jul 29, 2026
StartActual
Sep 24, 2026
Primary completionEst.
Mar 23, 2027
CompletionEst.
Aug 1, 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 21, 2026
Sites
1 site added — first site in United States
Show site
  • Penn Medicine · Philadelphia, United States
Oct 21, 2026
Start date
Sep 1, 2026→Sep 24, 2026 (actual)
Oct 21, 2026
Primary completion
Mar 1, 2027→Mar 23, 2027
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Penn Medicine · Philadelphia, United States
    Start date Sep 1, 2026→Sep 24, 2026 (now actual)
    Primary completion Mar 1, 2027→Mar 23, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07735286
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Sep 24, 2026
Primary completion
Mar 23, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Senior Project Manager, MSW
Contact
nathalie.laurent@pennmedicine.upenn.edu
609-534-0751
Cheryl Bettigole, MD, MPH
principal investigator · Penn Medicine
Jennifer Lee, MD
principal investigator · Penn Medicine
Mucio (Kit) Delgado, MD, MS
principal investigator · Penn Medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion